Current price is more than the intrinsic value

Intrinsic Value

Stock has not been able to generate better return on equity than bank FD

ROE vs FD rates

Stock doesn't offer attractive dividend returns

Dividend Returns

Good time to consider, as stock is not in overbought zone

Entry Point

Stock not in ASM/GSM lists and not a lot of promoter holding is pledged

No Red Flags

Bafna Pharma Standalone December 2021 Net Sales at Rs 20.46 crore, up 17.08% Y-o-Y

Bafna Pharmaceuticals standalone net profit rises 88.89% in the December 2021 quarter

Bafna Pharma in talks with multinational pharma firms for brand acquisition

Pharmaceuticals formulations major Bafna Pharmaceuticals Ltd was in advanced stage of discussion with some multi-national pharma companies for acquisitions of brands, a company official said.

In talks with MNCs pharma cos for acquisition of brands: Bafna pharma

​​The Earnings Before Interest Depreciation and Amortization (EBITDA) for the half year ending September 30, 2021 was at Rs 7.43 crore, as against Rs 4.28 crore registered in the same period of last financial year, the statement added.

In talks with multinational pharma cos for acquisition of brands: Bafna pharmaceuticals

The company in particular seeks ‘Rights Issue’ to meet its capital requirements.

Bafna Pharma board to consider various avenues for raising funds

Bafna Pharmaceuticals standalone net profit rises 15.47% in the June 2021 quarter

Onward Technologies Ltd, Sangam (India) Ltd, Bafna Pharmaceuticals Ltd and CHD Chemicals Ltd are among the other losers in the BSE’s ‘B’ group today, 22 July 2021.

Shakti Pumps (India) Ltd leads losers in ‘B’ group

Bafna Pharmaceuticals reports standalone net profit of Rs 2.64 crore in the March 2021 quarter

The packaging lines have received approval from the UK-MHRA (Medicines and Healthcare products Regulatory Agency) for the United Kingdom and the European Union (EU).

Bafna Pharma adds two fully automated packaging lines to existing capacity; Stock hits 5% upper circuit

Bafna Pharmaceuticals hit an upper circuit of 5% at Rs 135.15 after the UK drug regulator approved the company’s two newly added automated packaging lines.

Bafna Pharma spurts after UK MHRA approval for packaging lines

Bafna Pharmaceuticals Limited is a pharmaceutical company. The Company is engaged in the manufacture of drugs and medicines. The Company operates through generic pharmaceutical segment. The Company caters to both domestic and international markets. Its HAEMATINIC products include Raricap, Raricap Forte, Raricap L Suspension, Raricap Combi, Raricap Drops, Raricap M, Raricap Maa and Raricap S Injection. Raricap is indicated for iron deficiency anemia. Raricap Forte is indicated for iron deficiency anemia in pregnancy and lactation. Raricap L Suspension is indicated for iron deficiency anemia in children. Raricap Combi is indicated for iron deficiency anemia and calcium deficiency during pregnancy and lactation. Raricap Drops is indicated for iron deficiency and iron deficiency anemia in infants and toddlers. Its other products include LoPIH, BSF, Drofenac, I-Gest-200, Molev Syrup, AFENAC-P, AFENAC TH, NOCAF Syrup, IZABOF 250 milligram (MG), IZABOF 500 MG and IZABOF Suspension.

Bafna Pharmaceuticals Ltd

Bafna Pharmaceuticals Ltd

Intrinsic Value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry Point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

Bafna Pharma Standalone December 2021 Net Sales at Rs 20.46 crore, up 17.08% Y-o-Y

Bafna Pharmaceuticals standalone net profit rises 88.89% in the December 2021 quarter

Bafna Pharma in talks with multinational pharma firms for brand acquisition

In talks with MNCs pharma cos for acquisition of brands: Bafna pharma

In talks with multinational pharma cos for acquisition of brands: Bafna pharmaceuticals

Bafna Pharma board to consider various avenues for raising funds

Bafna Pharmaceuticals standalone net profit rises 15.47% in the June 2021 quarter

Bafna Pharmaceuticals Ltd

Intrinsic ValueIntrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD ratesFixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend ReturnsA dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry PointHigh demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

Bafna Pharma Standalone December 2021 Net Sales at Rs 20.46 crore, up 17.08% Y-o-Y

Bafna Pharmaceuticals standalone net profit rises 88.89% in the December 2021 quarter

Bafna Pharma in talks with multinational pharma firms for brand acquisition

In talks with MNCs pharma cos for acquisition of brands: Bafna pharma

In talks with multinational pharma cos for acquisition of brands: Bafna pharmaceuticals

Bafna Pharma board to consider various avenues for raising funds

Bafna Pharmaceuticals standalone net profit rises 15.47% in the June 2021 quarter

Intrinsic Value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry Point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock